Market Overview

2 Micro-Cap Pharma Stocks Worth Watching

2 Micro-Cap Pharma Stocks Worth Watching
Related ANTH
35 Biggest Movers From Yesterday
32 Stocks Moving In Monday's Mid-Day Session
Related RCPI
Rock Creek Pharmaceuticals Announces Successful Completion of Phase I Clinical Trial to Evaluate Oral Formulations of its Lead Compound, Plans to Conduct Proof-of-Concept Trial in Subjects with Mild to Moderate Psoriasis
Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody Energy, Ballard Fall

In this week’s email to subscribers, independent trader and technical analyst Roberto Pedone commented on a few interesting small- and micro-cap stocks. Below is a look at two micro-cap biopharmaceutical stocks that he likes.

Anthera Pharmaceuticals

Anthera Pharmaceuticals Inc (NASDAQ: ANTH) is a Delaware-based biopharmaceutical company with a "nice looking ascending triangle chart setup" that looks ready to trigger over $5.10, to $5.25 and then beyond $5.33, Pedone said.

Related Link: Carl Icahn Micro-Cap Voltari Spikes Mysteriously

As it can be seen, the stock is "making higher lows over the last three months and now it's bouncing off both its 50-day at $4.54 and its 20-day at $4.69."

The analyst assured he would only play this if gets really robust volume, "since it's tried to break out a few times recently and failed." Support looks solid around $4.60.

Rock Creek Pharmaceuticals

Rock Creek Pharmaceuticals Inc (NASDAQ: RCPI) is a $17.1 million market cap pharmaceutical company that, according to Pedone, has a chance of becoming the next Cleveland BioLabs, Inc. (NASDAQ: CBLI).

Related Link: 2 Tech Micro Caps This Expert Is Watching

"Chart and share structure gives it a chance, so be on high alert for this one if it gets volume and starts ripping," the analyst said.

"I'm not 100 percent sure if Yahoo Finance has the float right for $RCPI at 7.3 million, but nonetheless the chart is primed. Over $2.03 and then its 20-day at $2.17 could set it off, so look for massive volume like $CBLI had on Tuesday," he added, concluding that this is a thin name, and one should only take it if comfortable trading these.

Image Credit: Public Domain

Latest Ratings for ANTH

Dec 2016JefferiesDowngradesBuyHold
Dec 2016CitigroupDowngradesBuyNeutral
Sep 2015CitigroupInitiates Coverage onBuy

View More Analyst Ratings for ANTH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Small Cap Analysis Technicals Analyst Ratings Trading Ideas


Related Articles (CBLI + ANTH)

View Comments and Join the Discussion!

Partner Center